| 000 | 01767 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514183517.0 | ||
| 264 | 0 | _c20040423 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a1088-5412 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVogelson, Cullen T | |
| 245 | 0 | 0 |
_aPreclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. _h[electronic resource] |
| 260 |
_bAllergy and asthma proceedings _c |
||
| 300 |
_a69-75 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Topical |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAllergens _xadverse effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Allergic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCapillary Permeability _xdrug effects |
| 650 | 0 | 4 |
_aCircadian Rhythm _xdrug effects |
| 650 | 0 | 4 |
_aConjunctivitis, Allergic _xdrug therapy |
| 650 | 0 | 4 |
_aDibenzoxepins _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGuinea Pigs |
| 650 | 0 | 4 |
_aHistamine H1 Antagonists _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOlopatadine Hydrochloride |
| 650 | 0 | 4 | _aOphthalmic Solutions |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAbelson, Mark B | |
| 700 | 1 | _aPasquine, Terri | |
| 700 | 1 | _aStephens, Donna M | |
| 700 | 1 | _aGamache, Daniel A | |
| 700 | 1 | _aGross, Robert D | |
| 700 | 1 | _aRobertson, Stella M | |
| 700 | 1 | _aYanni, John M | |
| 773 | 0 |
_tAllergy and asthma proceedings _gvol. 25 _gno. 1 _gp. 69-75 |
|
| 999 |
_c14771912 _d14771912 |
||